The osteoporosis revolution

Annals of Internal Medicine

Volumn 126, Issue 6, 1997, Pages 458-462

  Raisz, Lawrence G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; CALCITONIN; CALCIUM; DROLOXIFENE; ESTROGEN; FLUORIDE SODIUM; PARATHYROID HORMONE; RALOXIFENE; TAMOXIFEN; VITAMIN D;

BONE ATROPHY; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CALCIUM INTAKE; ENDOMETRIUM CANCER; ESTROGEN THERAPY; GENETIC SUSCEPTIBILITY; HUMAN; OSTEOPOROSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VITAMIN INTAKE;

EID: 0031043491     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-6-199703150-00007     Document Type: Review

References (56)

1. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone. 1994;15:377-86.
2. Clark AP, Schuttinga JA. Targeted estrogen/progesterone replacement therapy for osteoporosis: calculation of health care cost savings. Osteoporos Int. 1992;2:195-200.
3. Jonsson B, Christiansen C, Johnell O, Hedbrandt J. Cost-effectiveness of fracture prevention in established osteoporosis Osteoporos Int. 1995;5:136-42.
4. Melton LJ 3d. Hip fractures: a worldwide problem today and tomorrow. Bone. 1993;14(Suppl 1):S1-8.
5. Lindsay R. The burden of osteoporosis: cost. Am J Med. 1995;98(2A):9S-11S.
6. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC Jr. Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res. 1991;6:561-7.
7. Tokita A, Kelly PJ, Nguyen TV, Risteli L, Qi JC, Morrison NA, et al. Genetic influences on type I collagen synthesis and degradation: further evidence for genetic regulation of bone turnover. J Clin Endocrinol Metab. 1994;78:1461-6.
8. Seeman E, Tsalamandris C, Formica C, Hopper JL, McKay J. Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. J Bone Miner Res. 1994;9:739-43.
9. Jacobsen SJ, Cooper C, Gottlieb MS, Goldberg J, Yahnke DP, Melton LJ 3d. Hospitalisation with vertebral fracture among the aged: a national population-based study. Epidemiology. 1992;3:515-8.
10. White CP, Morrison NA, Gardiner EM, Eisman JA. Vitamin D receptor alleles and bone physiology. J Cell Biochem. 1994;56:307-14.
11. Krall EA, Parry P, Lichter JB, Dawson-Hughes B. Vitamin D receptor alleles and rates of bone loss: influences of years since menopause and calcium intake. J Bone Miner Res. 1995;10:978-84.
12. Ferrari S, Rizzoli R, Chevalley T, Slosman D, Eisman JA, Bonjour JP, Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density. Lancet. 1995;345:423-4.
13. Eisman JA. Vitamin D receptor gene alleles and osteoporosis: an affirmative view. J Bone Miner Res. 1995;10:1289-93.
14. Peacock M. Vitamin D receptor gene alleles and osteoporosis: a contrasting view. J Bone Miner Res. 1995;10:1294-7.
15. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med. 1988;318:818-28.
16. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, et al. Regulation of interleukin-6, osleoclastogenesis, and bone mass by androgens. J Clin Invest. 1995;95:2886-95.
17. Kawaguchi H, Pilbeam CC, Vargas SJ, Morse EE, Lorenzo JA, Raisz LG. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest. 1995;96:539-48.
18. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology. 1995;136:3054-61.
19. Ralston SH. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. J Bone Miner Res. 1994;9:883-90.
20. Bismar H, Diel I, Ziegler R, Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab. 1995;80:3351-5.
21. Kassem M, Khosla S, Spelsberg TC, Riggs BL. Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. J Clin Endocrinol Metab. 1996;81:513-8.
22. Kassem M, Brixen K, Blum W, Mosekilde L, Eriksen EF. No evidence for reduced spontaneous or growth-hormone-stimulated serum levels of insulin-like growth factor (IGF)-I, IGF-II or IGF binding protein 3 in women with spinal osteoporosis. Eur J Endocrinol. 1994;131:150-5.
23. Ravn P, Overgaard K, Spencer EM, Christiansen C. Insulin-like growth factors I and II in healthy women with and without established osteoporosis. Eur J Endocrinol. 1995;132:313-9.
24. Consensus Development Conference on Osteoporosis. Hong Kong, 1-2 April 1993. Am J Med. 1993;95:1S-78S.
25. Kanis JA, Melton LJ 3d, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-41.
26. Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med. 1995;98:24S-28S.
27. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72-5.
28. Rizzoli R, Slosman D, Bonjour JP. The role of dual energy x-ray absorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis. Am J Med. 1995;98:33S-6S.
29. Gonnelli S, Cepollaro C, Agnusdei D, Palmieri R, Rossi S, Gennari C. Diagnostic value of ultrasound analysis and bone densitometry as predictors of vertebral deformity in postmenopausal women. Osteoporos Int. 1995;5:413-8.
30. Delmas PD. Biochemical markers of bone turnover. J Bone Miner Res. 1993;8(Suppl 2):549-55.
31. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ. 1991;303:961-4.
32. Riis BJ. The role of bone loss. Am I Med. 1995;98(2A):29S-32S.
33. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab. 1995;80:864-8
34. Garnaro P, Shih W, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-700.
35. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab. 1994;79:366-71.
36. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase II Osteoporosis Treatment Study Group. N Engl J Med 1995,333:1437-43.
37. Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med. 1995;98:452-8.
38. Chapuy MC, Arlot MR, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ. 1994;309:1081-2.
39. Prestwood KM, Pilbeam CC, Raisz LG. Treatment of osteoporosis Annu Rev Med. 1995;46:249-56
40. Davidson NE. Hormone-replacement therapy - breast versus heart versus bone. N Engl J Med. 1995;332:1638-9.
41. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062-71.
42. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
43. Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG. The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab. 1995;80:3287-91.
44. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci. 1995;761:355-60.
45. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology. 1995;136:2435-41.
46. Kleerekoper M, Mendlovic DB. Sodium fluoride therapy of postmenopausal osteoporosis. Endocr Rev. 1993;14:312-23.
47. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 1995;123:401-8.
48. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993;14:690-709.
49. Raisz LG, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab. 1996;81:37-43.
50. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 1992;7:1063-9.
51. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
52. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid bone loss. Osteoporos Int. 1993;3(Suppl 1):141-3.
53. Rodan GA. Good hope for making osteoporosis a disease of the past. Osteoporos Int. 1994;4(Suppl 1):5-6.
54. Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health. 1994;18:153-60.
55. Kanis JA. Treatment of osteoporosis in elderly women. Am J Med. 1995;98(2A):60S-6S.
56. Black DM. Why elderly women should be screened and treated to prevent osteoporosis. Am J Med. 1995;98(2A):67S-75S.